Evidence map›Paper›PMID 40596712›Full record

ArticleNPJ precision oncology2025

The responses of HNSCC patients to immunotherapy are shown by two novel co-expression patterns.

Narmeen Daher-Ghanem, Shay Sharon, Derrick Tao, Zhaoyu Sun, Wesley Rosales, Venkatesh Rajamanickam, Ryan Meng, Lakhvir Kaur, Brady Bernard, Brian Piening and 3 more

Abstract read
In one paragraph

Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Narmeen Daher-Ghanem *The Institute of Biomedical and Oral Research, The Hebrew University of Jerusalem, Jerusalem, Israel.
Shay Sharon *Department of Oral and Maxillofacial Surgery, Hadassah Medical Center, Faculty of Dental Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel. sharonshay@gmail.com.
Derrick TaoEarle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Portland Medical Center, Portland, OR, USA.
Zhaoyu SunEarle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Portland Medical Center, Portland, OR, USA.
Wesley RosalesEarle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Portland Medical Center, Portland, OR, USA.
Venkatesh RajamanickamEarle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Portland Medical Center, Portland, OR, USA.
Ryan MengEarle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Portland Medical Center, Portland, OR, USA.
Lakhvir KaurEarle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Portland Medical Center, Portland, OR, USA.
Brady BernardEarle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Portland Medical Center, Portland, OR, USA.
Brian PieningEarle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Portland Medical Center, Portland, OR, USA.
Marcus CoueyDepartment of Oral and Maxillofacial Surgery, Boston University Henry M. Goldman School of Dental Medicine, Boston, MA, USA.
Michael J GoughEarle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Portland Medical Center, Portland, OR, USA.
Nataly Kravchenko-BalashaThe Institute of Biomedical and Oral Research, The Hebrew University of Jerusalem, Jerusalem, Israel. natalyk@ekmd.huji.ac.il.

Funding

Israel Science Foundation (ISF) 1961/19
6 · The paper itself

Abstract

Treatment of head and neck squamous cell carcinoma (HNSCC) is complex, with immunotherapy demonstrating potential yet facing challenges due to the tumor's unique immune microenvironment. Biomarker expression has been employed to predict immune responses, albeit with limited efficacy. We predicted that due to the complexity of the immune response, no singular biomarker could consistently forecast the efficacy of immunotherapy. Consequently, we implemented a multi-index strategy that encompassed a comprehensive study of the networks associated with HNSCC. Secretomes from 72 explants obtained from six HNSCC patients (comprising 72 secretome profiles: 18 untreated and 54 treated) were subjected to an information-theoretic analysis. The resultant phenotypes were corroborated in two external cohorts (TCGA, n = 518; GEO GSE159067, n = 102). This methodology revealed two reproducible co-expression phenotypes-Activation (Act) and Infiltration (Inf)-that were significantly correlated with T-cell functionality. Only tissues exhibiting both Act and Inf phenotypes demonstrated a favorable response to anti-PD-1 and anti-GITR ex vivo, and displayed an increased presence of CD8+ T-cells in proximity to cancer cells. External validation in two different RNA-seq cohorts reproduced the two phenotypes and verified that patients possessing both signatures had significantly prolonged overall survival following PD-1/PD-L1 therapy. This study emphasizes the importance of multiple-index characterization of HNSCC tissues in enhancing patient classification and predicting immunotherapy efficacy.

Identifiers

PMID40596712
PMCPMC12217146

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.